Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT03460327
Recruiting Observational

Bariatric Surgery and Pharmacokinetics of Candesartan

NCT03460327 · tracked via the Priya Life Science Norway tracker
Sponsor
Norwegian University of Science and Technology
Phase
Observational
Started
2016-11-02
Last updated
2026-07-08

Condition(s) studied

Obesity, Morbid

Investigational drug(s) / intervention(s)

Candesartan →

Candesartan: Patients are tested for their normal prescription candesartan medication

Study summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St. Olavs University Hospital Trondheim Norway Recruiting

On this site

📄 Atacand (candesartan) drug profile →

More Norwegian University of Science and Technology trials in Norway

Multimodal Assesment of Alzheimer Patients Recruiting
Bariatric Surgery and Pharmacokinetics of Metoprolol Recruiting
Bariatric Surgery and Pharmacokinetics of Ibuprofen Recruiting
Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance Active, not recruiting
Effect of Exercise Training on Breastmilk Composition Active, not recruiting

Other trials for the same condition

Bariatric Surgery and Pharmacokinetics of Metoprolol Recruiting
Bariatric Surgery and Pharmacokinetics of Ibuprofen Recruiting
Bariatric Surgery and Pharmacokinetics of Lamotrigine Recruiting
Bariatric Surgery and Pharmacokinetics of Valsartan Recruiting
Bariatric Surgery and Pharmacokinetics of Ramipril Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03460327 on ClinicalTrials.gov ↗ ← All trials in Norway